ArticleBioactive materials2025
Bifunctional adECM bioscaffold with STIM1-ASCs and IGF-2 promotes functional masseter VML repair via myogenesis and fibrosis suppression.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Differentiation of arterioles and capillaries in human blood vessel organoids with decellularized splenic matrix.Bioactive materials · 2026Article
- Multifunctional PDGF Nanofiber and MnCe Nanozyme-Incorporated Composite Hydrogel for Enhanced Skeletal Muscle Regeneration.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- [Frontier research on smart delivery biomaterials in the field of oral tissue engineering].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Review
- Pre-priming cell sheet therapy enabled by dynamic wrinkled electroactive substrate for muscle reconstruction.Bioactive materials · 2026Article
- From Design to Application: Advanced Cellulose Scaffolds for Engineered Tissue Regeneration.Polymers · 2026Review
- Biomimetic Scaffolds and Extracellular Matrix-Based Strategies for Myofiber Regeneration in Volumetric Muscle Loss.Drug design, development and therapy · 2026Review
- A LRELHLNNN-Gal‑3 Modified Adipose Decellularized Scaffold To Construct Colorectal Cancer Model for Anticancer Drug Screening and Immunotherapy.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Craniofacial muscles are essential for a variety of functions, including fine facial expressions. Severe injuries to these muscles often lead to more devastating consequences than limb muscle injuries, resulting in the loss of critical functions such as mastication and eyelid closure, as well as facial aesthetic impairment. Therefore, the development of targeted repair strategies for craniofacial muscle injuries is crucial. In this study, we engineered an adipose-derived decellularized extracellular matrix (adECM) bioscaffold co-loaded with seed cells and bioactive factors. The seed cells were STIM1-overexpressing adipose-derived stem cells (STIM1-ASCs), which exhibit directed and highly efficient myogenic differentiation, addressing the low differentiation efficiency of conventional ASCs that limits muscle regeneration. The bioactive factor used was insulin-like growth factor-2 (IGF-2), which modulates the immune microenvironment by reprogramming mitochondrial energy metabolism to promote M2 macrophage polarization. These M2 macrophages further suppress fibroblast collagen deposition, alleviating muscle fibrosis, while simultaneously enhancing the myogenic differentiation of STIM1-ASCs and myotube formation. Together, the recellularized adECM bioscaffold harnesses these dual mechanisms (promoting functional muscle regeneration and anti-fibrotic repair) to significantly improve the recovery of volumetric muscle loss (VML) in the masseter. The development of this bifunctional bioscaffold offers a novel therapeutic strategy and theoretical foundation for treating severe craniofacial muscle injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.